214 related articles for article (PubMed ID: 38042879)
1. Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Kvasnička A; Friedecký D; Brumarová R; Pavlíková M; Pavelcová K; Mašínová J; Hasíková L; Závada J; Pavelka K; Ješina P; Stibůrková B
Arthritis Res Ther; 2023 Dec; 25(1):234. PubMed ID: 38042879
[TBL] [Abstract][Full Text] [Related]
2. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
3. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
4. Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
Cao L; Zhao T; Xie C; Zheng S; Wan W; Zou H; Zhu X
J Immunol Res; 2021; 2021():5550626. PubMed ID: 33884273
[TBL] [Abstract][Full Text] [Related]
5. Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
Honda M; Horiuchi H; Torii T; Nakajima A; Iijima T; Murano H; Yamanaka H; Ito S
BMC Pediatr; 2021 Dec; 21(1):581. PubMed ID: 34922491
[TBL] [Abstract][Full Text] [Related]
6. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Urate Lowering Therapies.
Kang EH; Kim SC
Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
[TBL] [Abstract][Full Text] [Related]
8. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
Hashimoto H; Takeuchi M; Kawakami K
Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
[TBL] [Abstract][Full Text] [Related]
9. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
Premachandra KH; Day RO; Roberts DM
Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):245-251. PubMed ID: 33399392
[TBL] [Abstract][Full Text] [Related]
10. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Mod Rheumatol; 2021 Jan; 31(1):261-269. PubMed ID: 32552370
[TBL] [Abstract][Full Text] [Related]
11. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Terkeltaub R
Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
[TBL] [Abstract][Full Text] [Related]
12. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
13. Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat.
Yang F; Shi W; Wang L; Qin N; Wang C; Guo Y; Xu G; Fang J; Yu X; Ma Q
BMC Complement Med Ther; 2021 Jun; 21(1):175. PubMed ID: 34172058
[TBL] [Abstract][Full Text] [Related]
14. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
15. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
16. [Gout].
Tausche AK
Internist (Berl); 2021 May; 62(5):513-525. PubMed ID: 33721041
[TBL] [Abstract][Full Text] [Related]
17. How should we manage asymptomatic hyperuricemia?
Chalès G
Joint Bone Spine; 2019 Jul; 86(4):437-443. PubMed ID: 30316974
[TBL] [Abstract][Full Text] [Related]
18. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
19. Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout.
Wei J; Choi HK; Dalbeth N; Lane NE; Wu J; Lyu H; Zeng C; Lei G; Zhang Y
Arthritis Rheumatol; 2023 Aug; 75(8):1456-1465. PubMed ID: 36940260
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]